Arca
Skip to content
Tools
Tools

EEF2: Elongation factor 2

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Catalyzes the GTP-dependent ribosomal translocation step during translation elongation.

  • Drugs that act on it: 11
  • Approved: 3
  • In phases 1 to 3: 8
  • Sponsors: 7

Who Is On It, and How Far Along

Every drug ChEMBL records acting on EEF2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody-drug conjugate
  • Protein or peptide
  • Other

Approved3

  • Tagraxofusp
  • Denileukin diftitox
  • Moxetumomab pasudotox

Phase 32

  • Cintredekin besudotox
  • Oportuzumab monatox

Phase 24

  • LMB-1
  • LMB-100
  • LMB-2
  • Resimmune

Phase 12

  • LMB-7
  • LMB-9

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

  • Beijing VDJBio Co., LTD.19%
  • Sesen Bio, Inc.19%
  • Virogen Biotechnology Inc.19%

Modalities

Drugs on this target by ChEMBL molecule type.

  • Antibody-drug conjugate218%
  • Protein or peptide327%
  • Other655%

The Landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 10 of 11 act as: Elongation factor 2 inhibitor; the rest name their own mechanism.
TagraxofuspApprovedMenarini GroupProtein or peptideInhibitor—14Boxed warning
Denileukin diftitoxApprovedBeijing VDJBio Co., LTD.Protein or peptideInhibitor—4Boxed warning
Moxetumomab pasudotoxApprovedInnate PharmaAntibody-drug conjugateInhibitor—1Boxed warning
Cintredekin besudotoxPhase 3Insys TherapeuticsProtein or peptideInhibitor—0—
Oportuzumab monatoxPhase 3Sesen Bio, Inc.Antibody-drug conjugateInhibitor—0—
LMB-1Phase 2—OtherInhibitor—0—
LMB-100Phase 2RocheOtherDisrupting agentElongation factor 2 disrupting agent0—
LMB-2Phase 2—OtherInhibitor—0—
ResimmunePhase 2Virogen Biotechnology Inc.OtherInhibitor—0—
LMB-7Phase 1—OtherInhibitor—0—
LMB-9Phase 1—OtherInhibitor—0—

Open Trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 13 in all, from ClinicalTrials.gov.
Phase I Trial of Subcutaneous VDJ010 In Healthy Subjects and Patients With Ulcerative ColitisDenileukin diftitoxPhase 1RecruitingBeijing VDJBio Co., LTD.2026-11-12
A Registry-study of ELZONRIS in Participants With BPDCNTagraxofusp—RecruitingStemline Therapeutics, Inc.2026-08-25
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and VenetoclaxTagraxofuspPhase 1 / Phase 2RecruitingJacqueline Garcia, MD2025-08-29
HCW9302 (Interleukin-2 Fusion Protein) for Alopecia AreataDenileukin diftitoxPhase 1RecruitingHCW Biologics2025-07-03
Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm PatientsTagraxofuspPhase 2RecruitingFrench Innovative Leukemia Organisation2025-06-05
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive LifileucelDenileukin diftitoxPhase 1 / Phase 2RecruitingIovance Biotherapeutics, Inc.2025-04-23
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AMLTagraxofuspPhase 1 / Phase 2RecruitingStanford University2024-08-19
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell TransplantTagraxofuspPhase 1RecruitingCity of Hope Medical Center2024-07-12
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive ChemotherapyTagraxofuspPhase 2Active, not recruitingStemline Therapeutics, Inc.2024-06-13
Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or DeclinedTagraxofuspEarly phase 1RecruitingUniversity of Kansas Medical Center2024-05-16
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic MalignanciesTagraxofuspPhase 1RecruitingTherapeutic Advances in Childhood Leukemia Consortium2022-07-27
T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid TumorsDenileukin diftitoxPhase 1 / Phase 2Active, not recruitingAlexander B Olawaiye, MD2022-01-20
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell LeukemiaMoxetumomab pasudotoxPhase 1Active, not recruitingNational Cancer Institute (NCI)2019-01-16

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Spinocerebellar ataxia type 26
0.60
Primary cutaneous T-cell non-Hodgkin lymphoma
0.54
Neoplasm
0.54
Neurodegenerative disease
0.49
Hydrocephalus
0.46
Parkinson disease
0.42
Alzheimer disease
0.42
Lysosomal storage disease
0.41
CD4+/CD56+ hematodermic neoplasm
0.41
Neurodevelopmental disorder
0.40

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1795108, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P13639, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.